李开亮司全金△ 张帷.双联抗血小板治疗急性冠脉综合征临床疗效观察[J].现代生物医学进展英文版,2011,11(7):1305-1307. |
双联抗血小板治疗急性冠脉综合征临床疗效观察 |
Clinical study of dual anti-platelet for patients with acutecoronary syndrome |
|
DOI: |
中文关键词: 联抗血小板 氯吡格雷 阿司匹林 急性冠脉综合征 |
英文关键词: dual anti-platelet clopidogrel aspirin acute coronary syndrome |
基金项目: |
|
Hits: 944 |
Download times: 1075 |
中文摘要: |
目的:探讨双联抗血小板治疗急性冠脉综合征(ACS)的临床疗效和安全性。方法:60 例ACS 患者随机分为治疗组和对照
组。对照组给予阿司匹林单抗血小板治疗,治疗组采用阿司匹林+ 氯吡格雷双联抗血小板治疗,治疗3 个月后评价临床疗效。结
果:治疗组临床疗效总有效率为93.3%,显著高于对照组(76.7%),相比较有显著性差异(P<0.05);治疗后,两组LVEF、CO 、E/A 显
著上升,与治疗前比较均有显著性差异(P<0.05);且治疗组与对照组比较有显著性差异(P<0.05)。结论:阿司匹林和氯吡格雷双联
抗血小板药物治疗ACS,可以强化对血小板聚集的抑制,并增强抗栓效果,值得临床应用。 |
英文摘要: |
Objective: To investigate the clinical efficacy and safety of dual anti-platelet for treating the patients with acute coronary
syndrome (ACS).Methods: A total of 60 patients with ACS were randomly divided into the treatment group and control group. The control
group's patients were given the mono anti-platelet therapy of aspirin, and the treatment group's patients were given the dual anti-platelet
treatment of aspirin combined with clopidogrel. The clinical efficacy was observed after treatment for 3 months. Results: The total effective
rate of treatment group was 93.3%, the control group was 76.7%, compared the difference was significant (P <0.05); After therapy
the LVEF, CO and E / A of the two groups increased significantly, compared with the prior-treatment the difference was significant (P
<0.05), and the difference was significant between the treatment group and control group (P <0.05). Conclusion: The dual anti-platelet of
aspirin combined with clopidogrel for treating the patients with ACS can enhance the inhibition of platelet aggregation and enhance the
antithrombotic effect. It is worthy of clinical application. |
View Full Text
View/Add Comment Download reader |
Close |